Objective： To investigate the effects of rosiglitazone, a synthetic ligand of peroxisome proliferators-activated receptor gamma （PPARγ）, on the expression of acyl-coenzyme A： cholesterol acyltransferase-1 （ACAT-...Objective： To investigate the effects of rosiglitazone, a synthetic ligand of peroxisome proliferators-activated receptor gamma （PPARγ）, on the expression of acyl-coenzyme A： cholesterol acyltransferase-1 （ACAT-1） in phorbol myristate acetate （PMA）-pretreated THP-1 cells after the inducement of advanced glycation end products （AGEs）. Methods： After THP-1 cells were cultured in the presence of 0.1 μmol/L PMA for 72 h to induce phagocytic differentiation, the obtained THP-1 macrophages were treated with rosiglitazone for 4 h at different concentrations （1, 5 or 10 μmol/L） and then exposed to AGEs-modified bovine serum albumin （AGEs-BSA） for 24 h at a concentration of 200 mg/L. Reverse transcription polymerase chain reaction （RT-PCR） and Western blot analysis were performed to detect the mRNA and protein expressions of ACAT-1 respectively. Results： Administration of AGEs-BSA （200 mg/L） into the THP-1 macrophages resulted in up-regulation of ACAT-1 at mRNA and protein levels when compared with the expressions in macrophages incubated with serum-free RPMI1640. Pretreatment of rosiglitazone inhibited significantly the increased expression of ACAT-1 induced by AGEs-BSA in a concentration-dependent manner. Conclusion： PPARy activation by rosiglitazone down-regulates ACAT-1 expression induced by AGEs in THP-1 macrophages, which might provide a new way for treating atherogenesis in diabetic patients.展开更多
文摘Objective： To investigate the effects of rosiglitazone, a synthetic ligand of peroxisome proliferators-activated receptor gamma （PPARγ）, on the expression of acyl-coenzyme A： cholesterol acyltransferase-1 （ACAT-1） in phorbol myristate acetate （PMA）-pretreated THP-1 cells after the inducement of advanced glycation end products （AGEs）. Methods： After THP-1 cells were cultured in the presence of 0.1 μmol/L PMA for 72 h to induce phagocytic differentiation, the obtained THP-1 macrophages were treated with rosiglitazone for 4 h at different concentrations （1, 5 or 10 μmol/L） and then exposed to AGEs-modified bovine serum albumin （AGEs-BSA） for 24 h at a concentration of 200 mg/L. Reverse transcription polymerase chain reaction （RT-PCR） and Western blot analysis were performed to detect the mRNA and protein expressions of ACAT-1 respectively. Results： Administration of AGEs-BSA （200 mg/L） into the THP-1 macrophages resulted in up-regulation of ACAT-1 at mRNA and protein levels when compared with the expressions in macrophages incubated with serum-free RPMI1640. Pretreatment of rosiglitazone inhibited significantly the increased expression of ACAT-1 induced by AGEs-BSA in a concentration-dependent manner. Conclusion： PPARy activation by rosiglitazone down-regulates ACAT-1 expression induced by AGEs in THP-1 macrophages, which might provide a new way for treating atherogenesis in diabetic patients.
